Disclosed herein are methods of treating a subject having an autoimmune or inflammatory
disease, and formulations associated therewith, comprising administering to the patient a compound of (S)-5-benzyl-N-(7-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-
triazole-3-
carboxamide, or a pharmaceutically acceptable salt thereof, wherein the compound or the pharmaceutically acceptable salt is administered at a
dose of about 12.5 mg to about 125 mg
free base equivalent of said compound per
dose.